Homoarginine in patients with primary hyperparathyroidism

American Journal of the Medical Sciences

Volumn 349, Issue 4, 2015, Pages 306-311

  Tomaschitz, Andreas ^a,b,c   Verheyen, Nicolas ^a   Gaksch, Martin ^a   Meinitzer, Andreas ^a   Pieske, Burkert ^a,c   Kraigher Krainer, Elisabeth ^a,c   Colantonio, Caterina ^a   März, Winfried ^a,d,e   Schmidt, Albrecht ^a   Belyavskiy, Evgeny ^a   Rus Machan, Jutta ^b   Van Ballegooijen, Adriana J ^f   Stiegler, Claudia ^a   Amrein, Karin ^a   Ritz, Eberhard ^g   Fahrleitner Pammer, Astrid ^a   Pilz, Stefan ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b Specialist Clinic for Rehabilitation PV Bad Aussee   (Austria)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d SYNLAB ACADEMY   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Homoarginine; Parathyroid hormone; Primary hyperparathyroidism

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; CALCIUM; HEMOGLOBIN; HOMOARGININE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; 25-HYDROXYVITAMIN D; VITAMIN D;

ADULT; AGED; ALBUMIN BLOOD LEVEL; AMINO ACID BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; SMOKING; VITAMIN BLOOD LEVEL; WAIST HIP RATIO; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY;

AGED; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HOMOARGININE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; MALE; PARATHYROID HORMONE; VITAMIN D;

EID: 84927177840     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0000000000000419     Document Type: Article

References (39)

1. Tomaschitz A, Ritz E, Pieske B, et al. Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease. Cardiovasc Res 2012;94:10-9.
2. Ogard CG, Engelmann MD, Kistorp C, et al. Increased plasma N-terminal pro-B-type natriuretic peptide and markers of inflammation related to atherosclerosis in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf) 2005;63:493-8.
3. Amann K, Tornig J, Flechtenmacher C, et al. Blood-pressure-independent wall thickening of intramyocardial arterioles in experimental uraemia: evidence for a permissive action of PTH. Nephrol Dial Transpl 1995;10:2043-8.
4. Nuzzo V, Tauchmanova L, Fonderico F, et al. Increased intimamedia thickness of the carotid artery wall, normal blood pressure profile and normal left ventricular mass in subjects with primary hyperparathyroidism. Eur J Endocrinol 2002;147:453-9.
5. Morfis L, Smerdely P, Howes LG. Relationship between serum parathyroid hormone levels in the elderly and 24 h ambulatory blood pressures. J Hypertens 1997;15:1271-6.
6. Hagstrom E, Hellman P, Larsson TE, et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 2009;119:2765-71.
7. Pilz S, Tomaschitz A, Drechsler C, et al. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography. Eur Heart J 2010;31:1591-8.
8. van Ballegooijen A, Reinders I, Visser M, et al. Parathyroid hormone and cardiovascular disease events: a systematic review and metaanalysis of prospective studies. Am Heart J 2013;165:655-64.
9. Yu N, Donnan PT, Leese GP. A record linkage study of outcomes in patients with mild primary hyperparathyroidism: the Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxf) 2011;75:169-76.
10. Ogard CG, Engholm G, Almdal TP, et al. Increased mortality in patients hospitalized with primary hyperparathyroidism during the period 1977-1993 in Denmark. World J Surg 2004;28:108-11.
11. Bell EA. The isolation of L-homoarginine from seeds of Lathyrus cicera. Biochem J 1962;85:91-3.
12. Meinitzer A, Drechsler C, Tomaschitz A, et al. Homoarginine: a new cardiovascular risk marker in hemodialysis patients. J Lab Med 2011; 35:153-9.
13. van der Zwan LP, DavidsM, Scheffer PG, et al. L-Homoarginine and L-arginine are antagonistically related to blood pressure in an elderly population: the Hoorn study. J Hypertens 2013;31:1114-23.
14. Choe CU, Atzler D, Wild PS, et al. Homoarginine levels are regulated by L-arginine:glycine amidinotransferase and affect stroke outcome: results from human and murine studies. Circulation 2013;128:1451-61.
15. Atzler D, Rosenberg M, Anderssohn M, et al. Homoarginine-an independent marker of mortality in heart failure. Int J Cardiol 2013; 168:4907-9.
16. Pilz S, Tomaschitz A, Meinitzer A, et al. Low serum homoarginine is a novel risk factor for fatal strokes in patients undergoing coronary angiography. Stroke 2011;42:1132-4.
17. März W, Meinitzer A, Drechsler C, et al. Homoarginine, cardiovascular risk, and mortality. Circulation 2010;122:967-75.
18. Pilz S, Meinitzer A, Tomaschitz A, et al. Associations of homoarginine with bone metabolism and density, muscle strength and mortality: cross-sectional and prospective data from 506 female nursing home patients. Osteoporos Int 2013;24:377-81.
19. Pilz S, Meinitzer A, Tomaschitz A, et al. Homoarginine deficiency is associated with increased bone turnover. Osteoporos Int 2012;23: 2731-2.
20. Eastell R, Arnold A, Brandi ML, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009;94:340-50.
21. Tomaschitz A, Fahrleitner-Pammer A, Pieske B, et al. Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial. BMC Endocr Disord 2012;12:19.
22. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12.
23. Pilz S, Meinitzer A, Tomaschitz A, et al. Low homoarginine concentration is a novel risk factor for heart disease. Heart 2011;97:1222-7.
24. Tomaschitz A, Meinitzer A, Pilz S, et al. Homoarginine, kidney function and cardiovascular mortality risk. Nephrol Dial Transpl 2014;29: 663-71.
25. Ring M, Farahnak P, Gustavsson T, et al. Arterial structure and function in mild primary hyperparathyroidism is not directly related to parathyroid hormone, calcium, or vitamin D. PLoS One 2012;7:e39519.
26. Agarwal G, Nanda G, Kapoor A, et al. Cardiovascular dysfunction in symptomatic primary hyperparathyroidism and its reversal after curative parathyroidectomy: results of a prospective case control study. Surgery 2013;154:1394-403.
27. Boger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor. J Nutr 2004;134:2842-7.
28. Kleber ME, Seppala I, Pilz S, et al. Genome-wide association study identifies 3 genomic loci significantly associated with serum levels of homoarginine: the AtheroRemo Consortium. Circ Cardiovasc Genet 2013;6:505-13.
29. Jazwinska-Kozuba A, Martens-Lobenhoffer J, Kruszelnicka O, et al. Opposite associations of plasma homoarginine and ornithine with arginine in healthy children and adolescents. Int J Mol Sci 2013;14: 21819-32.
30. Toque HA, Nunes KP, Rojas M, et al. Arginase 1 mediates increased blood pressure and contributes to vascular endothelial dysfunction in deoxycorticosterone acetate-salt hypertension. Front Immunol 2013;4:219.
31. Guthmiller P, Van Pilsum JF, Boen JR, et al. Cloning and sequencing of rat kidney L-arginine:glycine amidinotransferase. Studies on the mechanism of regulation by growth hormone and creatine. J Biol Chem 1994;269:17556-60.
32. Lombardi G, Di Somma C, Vuolo L, et al. Role of IGF-I on PTH effects on bone. J Endocrinol Invest 2010;33:22-6.
33. Cheng SL, Fausto A, Janne OA, et al. Regulation of ornithine decarboxylase by parathyroid hormone in osteoblastic cell systems. Calcif Tissue Int 1992;51:370-5.
34. Goto H, Matsui-Yuasa I, Otani S, et al. Effects of parathyroid hormone on ornithine decarboxylase activity in human osteosarcoma cells. Arch Biochem Biophys 1991;286:316-22.
35. Humm A, Fritsche E, Steinbacher S, et al. Crystal structure and mechanism of human L-arginine:glycine amidinotransferase: a mitochondrial enzyme involved in creatine biosynthesis. EMBO J 1997; 16:3373-85.
36. Dumont J, Zureik M, Bauters C, et al. Association of OAZ1 gene polymorphisms with subclinical and clinical vascular events. Arterioscler Thromb Vasc Biol 2007;27:2120-6.
37. Takatsuka Y, Yamaguchi Y, Ono M, Kamio Y. Gene cloning and molecular characterization of lysine decarboxylase from Selenomonas ruminantium delineate its evolutionary relationship to ornithine decarboxylase from eukaryotes. J Bacteriol 2000;182:6732-41.
38. Shimizu M, Carter PH, Khatri A, et al. Enhanced activity in parathyroid hormone-(1-14) and -(1-11): novel peptides for probing ligandreceptor interactions. Endocrinology 2001;142:3068-74.
39. Caporale A, Schievano E, Peggion E. Peptide-peptoid hybrids based on (1-11)-parathyroid hormone analogs. J Pept Sci 2010;16:480-5.